

Human Anti-tumor Immunity: Insights from Immunoth

Immunity

52, 36-54

DOI: [10.1016/j.immuni.2019.12.010](https://doi.org/10.1016/j.immuni.2019.12.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	T-cell agonists in cancer immunotherapy. , 2020, 8, e000966.		69
2	Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factorâ€”tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma. <i>Pathology International</i> , 2020, 70, 712-723.	1.3	5
3	Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes. <i>Journal of Immunology Research</i> , 2020, 2020, 1-9.	2.2	2
4	Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses. <i>Biomedicines</i> , 2020, 8, 474.	3.2	24
5	The chemical biology of IL-12 production<i>via</i>the non-canonical NFκB pathway. <i>RSC Chemical Biology</i> , 2020, 1, 166-176.	4.1	11
6	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. <i>Biomarker Research</i> , 2020, 8, 35.	6.8	122
7	Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy. <i>Cancers</i> , 2020, 12, 2418.	3.7	17
8	<p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7229-7241.	2.0	12
9	Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 89.	8.6	157
10	Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses. <i>Frontiers in Oncology</i> , 2020, 10, 819.	2.8	46
11	Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 1295.	4.8	58
12	Promising targets based on pattern recognition receptors for cancer immunotherapy. <i>Pharmacological Research</i> , 2020, 159, 105017.	7.1	27
13	Intratumoral Delivery of a PD-1â€”Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. <i>Cancer Immunology Research</i> , 2020, 8, 632-647.	3.4	42
14	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. <i>Cancers</i> , 2020, 12, 927.	3.7	6
15	Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2378.	4.1	48
16	Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. <i>Cancer Control</i> , 2021, 28, 107327482110387.	1.8	8
17	Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO. <i>Frontiers in Immunology</i> , 2021, 12, 636081.	4.8	31
18	Targeting tumor-associated macrophages to synergize tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 75.	17.1	323

#	ARTICLE	IF	CITATIONS
19	Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. <i>Journal of Nanobiotechnology</i> , 2021, 19, 58.	9.1	67
20	Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-14.	4.0	40
21	The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. <i>Nature Communications</i> , 2021, 12, 1940.	12.8	76
22	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	6.4	113
23	STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	15
24	Endogenous Stimuli-Activatable Nanomedicine for Immune Theranostics for Cancer. <i>Advanced Functional Materials</i> , 2021, 31, 2100386.	14.9	36
25	Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. <i>Immunity</i> , 2021, 54, 737-752.e10.	14.3	58
26	Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCI) – insights of people affected by cancer and healthcare professionals: a qualitative study protocol. <i>BMJ Open</i> , 2021, 11, e043750.	1.9	3
27	Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response. <i>Journal of Hematology and Oncology</i> , 2021, 14, 98.	17.0	173
28	The Curcumin Analog GO-Y030 Controls the Generation and Stability of Regulatory T Cells. <i>Frontiers in Immunology</i> , 2021, 12, 687669.	4.8	16
29	Tumor Microenvironment Subtypes and Immune-Related Signatures for the Prognosis of Breast Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-12.	1.9	2
30	Novel Approaches of Dysregulating Lysosome Functions in Cancer Cells by Specific Drugs and Its Nanoformulations: A Smart Approach of Modern Therapeutics. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 5065-5098.	6.7	18
31	B7-H3/CD276: An Emerging Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 701006.	4.8	100
32	Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 1486-1509.	1.1	1
33	MAGE-3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma. <i>Cancer Communications</i> , 2021, 41, 1354-1372.	9.2	11
34	Small Extracellular Vesicles and Metastasis – Blame the Messenger. <i>Cancers</i> , 2021, 13, 4380.	3.7	11
36	Targeting of the tumor microenvironment by curcumin. <i>BioFactors</i> , 2021, 47, 914-932.	5.4	36
37	IRF4 is Correlated with the Conversion to a Th17-Like Phenotype in Regulatory T Cells from the Malignant Pleural Effusion. <i>International Journal of General Medicine</i> , 2021, Volume 14, 6009-6019.	1.8	7

#	ARTICLE	IF	CITATIONS
38	Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication. <i>Cancers</i> , 2021, 13, 4844.	3.7	15
39	Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 695006.	2.8	9
40	Polysaccharide-based nanomedicines for cancer immunotherapy: A review. <i>Bioactive Materials</i> , 2021, 6, 3358-3382.	15.6	74
41	A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy. <i>Chemical Engineering Journal</i> , 2021, 422, 130111.	12.7	20
42	Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. , 2021, 9, e003464.		60
43	Dynamic biomarkers indicate the immunological benefits provided by Ganoderma spore powder in post-operative breast and lung cancer patients. <i>Clinical and Translational Oncology</i> , 2021, 23, 1481-1490.	2.4	12
44	PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes. <i>Clinical Cancer Research</i> , 2021, 27, 1932-1940.	7.0	25
45	B7-H3 \bar{A} –4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 ⁺ tumor-infiltrating lymphocytes. <i>Science Advances</i> , 2021, 7, .	10.3	31
46	Construction of a new tumor immunity-related signature to assess and classify the prognostic risk of ovarian cancer. <i>Aging</i> , 2020, 12, 21316-21328.	3.1	6
47	Assessment of immune status of laryngeal squamous cell carcinoma can predict prognosis and guide treatment. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1199-1220.	4.2	10
48	Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. <i>Nature Communications</i> , 2021, 12, 6012.	12.8	140
51	PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NF κ B pathway. <i>Science Advances</i> , 2021, 7, eabh2148.	10.3	18
52	Advances in plant-derived natural products for antitumor immunotherapy. <i>Archives of Pharmacal Research</i> , 2021, 44, 987-1011.	6.3	12
53	Overview of Tumor Immunotherapy based on Indoleamine 2,3 Dioxygenase Inhibitors. , 2020, , .		1
55	Immunotherapy in older patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2022, 162, 76-98.	2.8	8
56	Assessment of systemic immune-inflammation index in predicting postoperative pulmonary complications in patients undergoing lung cancer resection. <i>Surgery</i> , 2022, 172, 365-370.	1.9	6
57	Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?. <i>Nature Reviews Cardiology</i> , 2022, 19, 522-542.	13.7	125
58	Bacteria-mediated tumor immunotherapy <i>via</i> photothermally-programmed PD1 expression. <i>Nanoscale Advances</i> , 2022, 4, 1577-1586.	4.6	3

#	ARTICLE	IF	CITATIONS
59	An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
60	Identification and validation a costimulatory molecule gene signature to predict the prognosis and immunotherapy response for hepatocellular carcinoma. <i>Cancer Cell International</i> , 2022, 22, 97.	4.1	7
61	Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer. <i>JAMA Network Open</i> , 2022, 5, e224637.	5.9	6
62	Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor. <i>Molecular Medicine</i> , 2022, 28, 34.	4.4	10
63	Multicellular modules as clinical diagnostic and therapeutic targets. <i>Trends in Cancer</i> , 2022, 8, 164-173.	7.4	10
64	Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions. <i>Seminars in Cancer Biology</i> , 2022, 86, 532-541.	9.6	14
65	Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. <i>Nature Communications</i> , 2022, 13, 1742.	12.8	213
66	Immune-related lncRNAs can predict the prognosis of acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 888-899.	2.8	4
67	Vaccine Based on Dendritic Cells Electroporated with an Exogenous Ovalbumin Protein and Pulsed with Invariant Natural Killer T Cell Ligands Effectively Induces Antigen-Specific Antitumor Immunity. <i>Cancers</i> , 2022, 14, 171.	3.7	2
68	Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 875525.	2.8	3
69	Time Rules the Efficacy of Immune Checkpoint Inhibitors in Photodynamic Therapy. <i>Advanced Science</i> , 2022, 9, e2200999.	11.2	11
70	Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 560-574.	1.8	3
72	The multifaceted role of autophagy in cancer. <i>EMBO Journal</i> , 2022, 41, e110031.	7.8	63
73	Regulation of intrinsic and extrinsic metabolic pathways in tumour-associated macrophages. <i>FEBS Journal</i> , 2023, 290, 3040-3058.	4.7	6
74	Derived Multiple Allogeneic Protein Paracrine Signaling (d-MAPPS) Enhances T Cell-Driven Immune Response to Murine Mammary Carcinoma. <i>Analytical Cellular Pathology</i> , 2022, 2022, 1-10.	1.4	0
75	Characterization of Immune-Related Alternative Polyadenylation Events in Cancer Immunotherapy. <i>Cancer Research</i> , 2022, 82, 3474-3485.	0.9	6
76	Multi-omics analysis for potential inflammation-related genes involved in tumour immune evasion via extended application of epigenetic data. <i>Open Biology</i> , 2022, 12, .	3.6	1
77	Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. <i>ELife</i> , 0, 11, .	6.0	23

#	ARTICLE	IF	CITATIONS
78	Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: A real-world analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	2
79	Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. <i>Journal of Experimental Medicine</i> , 2023, 220, .	8.5	14
80	Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7. <i>Cancer Science</i> , 2023, 114, 370-383.	3.9	6
81	Photodynamic amplified immune checkpoint-blockade therapy of self-delivery bioregulator via epigenetic reprogramming. <i>Chemical Engineering Journal</i> , 2023, 453, 139729.	12.7	2
82	Molecular Typing and Clinical Characteristics of Synchronous Multiple Primary Colorectal Cancer. <i>JAMA Network Open</i> , 2022, 5, e2243457.	5.9	7
83	Future directions in cancer immunotherapy with monoclonal antibodies. <i>Research Results in Pharmacology</i> , 2022, 8, 101-107.	0.4	0
84	Discovery and Validation of a SIT1-Related Prognostic Signature Associated with Immune Infiltration in Cutaneous Melanoma. <i>Journal of Personalized Medicine</i> , 2023, 13, 13.	2.5	0
85	FLIM of NAD(P)H in Lymphatic Nodes Resolves T-Cell Immune Response to the Tumor. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15829.	4.1	1
86	Current State of Cold Atmospheric Plasma and Cancer-Immunity Cycle: Therapeutic Relevance and Overcoming Clinical Limitations Using Hydrogels. <i>Advanced Science</i> , 2023, 10, .	11.2	12
87	Integrated analysis of the relation to tumor immune microenvironment and predicted value of <i>Stonin1</i> gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma. <i>BMC Cancer</i> , 2023, 23, .	2.6	0
88	A Bio-Liposome Activating Natural Killer Cell by Illuminating Tumor Homogenization Antigen Properties. <i>Advanced Science</i> , 2023, 10, .	11.2	7
89	The profile and prognostic value of circulating lymphocyte subsets in metastatic colon cancer. <i>International Immunopharmacology</i> , 2023, 117, 109848.	3.8	1
90	Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer. <i>Cell Death Discovery</i> , 2023, 9, .	4.7	12
91	Geographically weighted linear combination test for gene-set analysis of a continuous spatial phenotype as applied to intratumor heterogeneity. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	3.7	0
92	The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	4
93	Research Progress of Siglec-15 in Tumor Mechanism. <i>Advances in Clinical Medicine</i> , 2023, 13, 4545-4550.	0.0	0
94	Effect of stimulator of interferon genes (STING) signaling on radiation-induced chemokine expression in human osteosarcoma cells. <i>PLoS ONE</i> , 2023, 18, e0284645.	2.5	1
95	Immunotherapy and Cancer Stem Cells. , 2023, , 165-235.		0

#	ARTICLE	IF	CITATIONS
96	Viral Vector-Based Gene Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7736.	4.1	9
97	Cuproptosis combines immune landscape providing prognostic biomarker in head and neck squamous carcinoma. <i>Heliyon</i> , 2023, 9, e15494.	3.2	0
98	Based on Network Pharmacology and Molecular Docking Technology, the Mechanism of Action of Maiwei Dihuang Pills on Idiopathic Pulmonary Fibrosis and Type 2 Diabetes Mellitus Was Explored. <i>Traditional Chinese Medicine</i> , 2023, 12, 887-904.	0.2	0
99	Proof of concept nanotechnological approach to in vitro targeting of malignant melanoma for enhanced immune checkpoint inhibition. <i>Scientific Reports</i> , 2023, 13, .	3.3	2
100	Leveraging various extracellular matrix levels to assess prognosis and sensitivity to immunotherapy in patients with ovarian cancer. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1
101	Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy. <i>ACS Nano</i> , 2023, 17, 10090-10103.	14.6	5
102	Doxorubicin Activity Is Modulated by Traditional Herbal Extracts in a 2D and 3D Multicellular Sphere Model of Leukemia. <i>Pharmaceutics</i> , 2023, 15, 1690.	4.5	1
103	Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	2
104	Gene expressions associated with longer lifespan and aging exhibit similarity in mammals. <i>Nucleic Acids Research</i> , 2023, 51, 7205-7219.	14.5	2
105	Influence of Laparoscopic Surgery on Cellular Immunity in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 3381.	3.7	1
106	Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications. <i>European Journal of Medicinal Chemistry</i> , 2023, 257, 115447.	5.5	5
107	Current Status of Immune Checkpoint Inhibitor Therapy in Patients with PD-L1 Low Expression/Negative Advanced NSCLC. <i>Advances in Clinical Medicine</i> , 2023, 13, 8248-8253.	0.0	0
108	PAD2: A potential target for tumor therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188931.	7.4	4
110	Overexpression of CD99 is associated with tumor adaptiveness and indicates the tumor recurrence and therapeutic responses in gliomas. <i>Translational Oncology</i> , 2023, 37, 101759.	3.7	3
111	Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans. <i>Communications Biology</i> , 2023, 6, .	4.4	2
112	MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer. <i>Journal of Ovarian Research</i> , 2023, 16, .	3.0	2
113	Cancer immunotherapy with enveloped self-amplifying mRNA CARG-2020 that modulates IL-12, IL-17 and PD-L1 pathways to prevent tumor recurrence. <i>Acta Pharmaceutica Sinica B</i> , 2023, , .	12.0	0
114	Cancer Cell Membrane Nanodiscs for Antitumor Vaccination. <i>Nano Letters</i> , 2023, 23, 7941-7949.	9.1	6

#	ARTICLE	IF	CITATIONS
115	Mass-produced gram-negative bacterial outer membrane vesicles activate cancer antigen-specific stem-like CD8 ⁺ T cells which enables an effective combination immunotherapy with anti-PD-1. <i>Journal of Extracellular Vesicles</i> , 2023, 12, .	12.2	3
116	Loss of cancer cell-derived <i>ADAM15</i> alters the tumor microenvironment in colorectal tumors. <i>International Journal of Cancer</i> , 2023, 153, 2068-2081.	5.1	0
117	Commensal bacterial hybrid nanovesicles improve immune checkpoint therapy in pancreatic cancer through immune and metabolic reprogramming. <i>Nano Today</i> , 2023, 52, 101993.	11.9	1
119	Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer. <i>Journal of Cellular and Molecular Medicine</i> , 0, , .	3.6	0
120	EPRIM: An approach of identifying cancer immune-related epigenetic regulators. <i>Molecular Therapy - Nucleic Acids</i> , 2024, 35, 102100.	5.1	0
121	Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1. <i>Nature Communications</i> , 2024, 15, .	12.8	0
122	Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer. <i>BMC Women's Health</i> , 2024, 24, .	2.0	0
123	An Adjuvant Micelle-Based Multifunctional Nanosystem for Tumor Immunotherapy by Remodeling Three Types of Immunosuppressive Cells. <i>ACS Nano</i> , 2024, 18, 3134-3150.	14.6	0
124	XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. <i>Cell Reports</i> , 2024, 43, 113600.	6.4	1
125	Knowledge mapping and current trends of m6A methylation in the field of cancer. <i>Heliyon</i> , 2024, 10, e26262.	3.2	0
126	Informing immunotherapy with multi-omics driven machine learning. <i>Npj Digital Medicine</i> , 2024, 7, .	10.9	0
127	High Intensity Focused Ultrasound-Driven Nanomotor for Effective Ferroptosis-Immuno-therapy of TNBC. <i>Advanced Science</i> , 2024, 11, .	11.2	0